Renovo, plc.

Renovo, plc. (lse: RNVO) is a biopharmaceutical company based in Manchester, UK. It is the world leader in scar prevention and reduction research, and it aims "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in 2009.

The US commercial market for prevention and reduction of scarring in the skin is valued at approximately US$4 billion per annum, and the market is larger in patient volume than Depression, Osteoporosis, Asthma and Diabetes.

Products
Currently the company doesn't have a marketed product, though its pipeline includes one drug that has recently initiated phase III clinical development, three drugs in phase II clinical development, and 13 other pre-clinical candidates.